Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 13/20 | 0.51 |
| ▸ | PARP11 | Q9NR21 | 10/20 | 0.51 |
| ▸ | PARP1 | P09874 | 10/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22981764 | 1.00 | PARP10 (0.51) | PARP10PARP11PARP1ACHERAF1 | |
| SCHEMBL22990374 | 0.88 | PARP10 (0.51) | PARP10PARP11PARP1ACHERAF1 | |
| SCHEMBL29698311 | 0.88 | PARP10 (0.51) | PARP10PARP11PARP1ACHERAF1 | |
| SCHEMBL27085865 | 0.84 | PIM1 (0.49) | PARP10PARP11 | |
| SCHEMBL22982078 | 0.83 | PARP10 (0.50) | PARP10PARP11PARP1ACHERAF1 | |
| SCHEMBL29698242 | 0.83 | PARP10 (0.50) | PARP10PARP11PARP1ACHERAF1 | |
| SCHEMBL23951998 | 0.76 | PARP10 (0.56) | PARP10PARP11PARP1ACHERAF1 | |
| SCHEMBL22990298 | 0.76 | PARP10 (0.56) | PARP10PARP11PARP1ACHERAF1 | |
| SCHEMBL23952300 | 0.76 | PARP10 (0.56) | PARP10PARP11PARP1ACHERAF1 | |
| SCHEMBL22982047 | 0.76 | PARP10 (0.56) | PARP10PARP11PARP1ACHERAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4010334-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | Novartis AG (CH) | 2022-06-15 | — | — | EP | disclosed |